PA
ENTA icon

Profund Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Profund Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-17,594
Closed -$377K – 1013
2023
Q2 		$377K Buy
17,594
+6,989
+66% +$206K 0.02% 606
2023
Q1 		$429K Buy
+10,605
New +$506K 0.03% 548
2018
Q4 		– Sell
-2,404
Closed -$205K – 1238
2018
Q3 		$205K Sell
2,404
-404
-14% -$40.5K 0.01% 1440
2018
Q2 		$325K Buy
+2,808
New +$280K 0.01% 1107

Other funds holding ENTA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Profund Advisors's ENTA Position: Q3 2023 in Review

Profund Advisors sold out of Enanta Pharmaceuticals (ENTA) in Q3 2023, closing a stake of 17,594 shares — an estimated $377K sold.

Profund Advisors first reported a position in ENTA in Q2 2018 and held it in 4 quarters. The position peaked at $429K in Q1 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q3 2023.

  • Profund Advisors reported no remaining Enanta Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Profund Advisors sold 17,594 Enanta Pharmaceuticals shares in Q3 2023, an estimated $377K.
  • Profund Advisors first reported a position in Enanta Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Profund Advisors's Enanta Pharmaceuticals position peaked at $429K in Q1 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2023.

Based on Profund Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.